GRNA Revenue first quarter 2023 Y/Y Growth Comment
Greenlight Biosciences Holdings Pbc achieved in the first quarter 2023, above Company average Revenue surge of 1369.23% year on year, to $ 3.82 millions.
Looking into first quarter 2023 results within Biotechnology & Pharmaceuticals industry 3 other companies have achieved higher Revenue growth. While Greenlight Biosciences Holdings Pbc' s Revenue doubling of 1369.23% ranks overall at the positon no. 87 in the first quarter 2023.
GRNA Revenue ( Y/Y Growth %)
2023
2022
2021
2020
4th Quarter
December
-
619.05 %
-
-
3rd Quarter
September
-
67.96 %
-
-
2nd Quarter
June
-
-
-
-
1st Quarter
March
1369.23 %
-21.21 %
-
-
FY
-
-
-
-
Financial Statements
Greenlight Biosciences Holdings Pbc's first quarter 2023 Revenue
Greenlight Biosciences Holdings Pbc achieved in the I. Quarter 2023 below company average Revenue jump of 26.49% quarter on quarter, to $ 3.82 millions.
Although the I. Quarter 2023 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the I. Quarter surge, eclipses the -38.1% growth in the I. Quarter a year ago
Within Biotechnology & Pharmaceuticals industry 24 other companies have achieved higher Revenue quarter on quarter growth. While Greenlight Biosciences Holdings Pbc's Revenue growth quarter on quarter, overall rank is 252.
Greenlight Biosciences Holdings Pbc achieved in the I. Quarter 2023 below company average Revenue jump of 26.49% quarter on quarter, to $ 3.82 millions.
I. Quarter 2023 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -38.1% in the I. Quarter a year ago.
Within Biotechnology & Pharmaceuticals industry 24 other companies have achieved higher Revenue quarter on quarter growth. While Greenlight Biosciences Holdings Pbc's Revenue growth quarter on quarter, overall rank is 252.
Greenlight Biosciences Holdings Pbc's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Mar 31 2023)
12 Months Ending (Dec 31 2022)
12 Months Ending (Sep 30 2022)
12 Months Ending (Jun 30 2022)
12 Months Ending (Mar 31 2022)
Cumulative Revenue 12 Months Ending
$ 10.34
$ 6.78
$ 4.17
$ 4.72
$ 0.26
Y / Y Revenue Growth (TTM)
-
-
-
-
-
Year on Year Revenue Growth Overall
Ranking
# 25
# 0
# 0
# 0
# 0
Seqeuential Revenue Change (TTM)
52.55 %
62.51 %
20.33 %
1734.63 %
-
Seq. Revenue Growth (TTM) Overall
Ranking
# 35
# 13
# 31
# 10
# 0
Cumulative Revenue growth Comment
Although Greenlight Biosciences Holdings Pbc's Annual Revenue growth year on year were below company's average 3924.51% , Revenue announced in the Mar 31 2023 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 1369.23% year on year, from % in Dec 31 2022. And, Greenlight Biosciences Holdings Pbc had the highest Revenue growth, in Biotechnology & Pharmaceuticals industry. In the Mar 31 2023 period, Greenlight Biosciences Holdings Pbc had cumulative twelve months Revenue of $ 10 millions compare to of $ -1 millions a year ago. Singns of progress, but modest, recording beneth usual 52.55 % Revenue advance, from $6.78 millions from the period from Dec 31 2022 to Mar 31 2022.
Among companies within the Healthcare sector 4 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 25.
Although Greenlight Biosciences Holdings Pbc's Annual Revenue growth year on year were below company's average 3924.51% , Revenue announced in the Mar 31 2023 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 1369.23% year on year, from % in Dec 31 2022. And, Greenlight Biosciences Holdings Pbc had the highest Revenue growth, in Biotechnology & Pharmaceuticals industry. In the Mar 31 2023 period, Greenlight Biosciences Holdings Pbc had cumulative twelve months Revenue of $ 10 millions compare to of $ -1 millions a year ago. Singns of progress, but modest, recording beneth usual 52.55 % Revenue advance, from $6.78 millions from the period from Dec 31 2022 to Mar 31 2022.
Among companies within the Healthcare sector 4 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 25.
About Greenlight Biosciences Holdings Pbc Revenue Growth Rates (GRNA), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
2,329.27%